Equities

Bioventus Inc

BVS:NSQ

Bioventus Inc

Actions
  • Price (USD)11.51
  • Today's Change0.10 / 0.88%
  • Shares traded291.29k
  • 1 Year change+198.96%
  • Beta0.8037
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold0
Sell1
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Bioventus Inc have a median target of 15.00, with a high estimate of 17.00 and a low estimate of 12.00. The median estimate represents a 30.32% increase from the last price of 11.51.
High47.7%17.00
Med30.3%15.00
Low4.3%12.00

Earnings history & estimates in USD

On Nov 05, 2024, Bioventus Inc reported 3rd quarter 2024 earnings of 0.06 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 3rd quarter results by 20.00%.
The next earnings announcement is expected on Mar 10, 2025.
Average growth rate+35.75%
Bioventus Inc reported annual 2023 earnings of 0.02 per share on Mar 12, 2024.
Average growth rate-85.22%
More ▼

Revenue history & estimates in USD

Bioventus Inc had 3rd quarter 2024 revenues of 138.96m. This bettered the 133.23m consensus of the 3 analysts covering the company. This was 16.72% above the prior year's 3rd quarter results.
Average growth rate+4.10%
Bioventus Inc had revenues for the full year 2023 of 512.35m. This was 0.04% above the prior year's results.
Average growth rate+17.69%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.